beta
Trial Radar IA
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery (Maigrir_OT) 40

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT06278285 (Maigrir_OT) è uno studio interventistico per Obesità, attualmente in arruolamento. Avviato il 6 marzo 2024, prevede di arruolare 40 partecipanti. Sotto la guida di Centre Hospitalier Universitaire de Nice, dovrebbe concludersi entro il 6 marzo 2027. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 27 marzo 2026.
Sommario breve
Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that su...Mostra di più
Titolo ufficiale

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Patologie
Obesità
Altri ID dello studio
  • Maigrir_OT
  • 21-AOIP-01
Numero NCT
NCT06278285
Data di inizio (effettiva)
2024-03-06
Ultimo aggiornamento pubblicato
2026-03-27
Data di completamento (stimata)
2027-03-06
Arruolamento (previsto)
40
Tipo di studio
Interventistico
FASE
N.D.
Stato
In arruolamento
Scopo principale
Diagnostico
Allocazione
Non randomizzato
Modello di intervento
In parallelo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Altrowhole blood in a GLP1
Oxytocyne assay in a GLP1 analogue or non-analogue patient population
Blood GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
Altrowhole blood in non analague patient population
Oxytocyne assay in a GLP1 analogue or non-analogue patient population
Blood No treated GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the ...Mostra di più
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Rate of oxytocin
show that subjects treated with a GLP-1 agonist have a significant change in oxytocin levels compared with subjects not treated with a GLP-1 agonist.
one time (before surgery)
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Fibrosis rate
compare adipose tissue caracteristics between patients treated by analog GLP1 and not treated by analog GLP1
At surgery
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Adulto, Adulto anziano
Età minima
18 Years
Sessi idonei
Tutti
  • Patient over 18 years of age.
  • Patient able to read and understand the information/consent leaflet.
  • Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
  • Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
  • Membership of a social security scheme
  • Patient's signed informed consent
  • For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
  • For non-GLP-1 analogue group: never taken GLP-1 analogues.

  • Pregnant or breast-feeding women.
  • Vulnerable patients (under guardianship)
  • Patients deprived of liberty
Centre Hospitalier Universitaire de Nice logoCentre Hospitalier Universitaire de Nice
Contatti principali dello studio
Contatto: ROUX Christian, PhD, +3349209220, [email protected]
Contatto: Iannelli Antonio, PhD, [email protected]
1 Centri dello studio in 1 paesi

Alpes-maritimes

CHU de Nice - Hôpital de l'Archet, Nice, Alpes-maritimes, 06200, France
Roux Christian, PhD, Contatto, +33492039220, [email protected]
Iannelli Antonio, PhD, Contatto, [email protected]
Iannelli Antonio, PhD, Investigatore principale
In arruolamento